HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by MIT Technology Review on January 16.
The article, “Manufacturing Organs” highlighted the new focus of Harvard Apparatus Regenerative Technology (HART) post spin-off. It noted the company is stepping up its production of synthetic tracheas to supply clinical trials.
Help employers find you! Check out all the jobs and post your resume.
